{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T20:28:52Z","timestamp":1778358532624,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20220617"],"award-info":[{"award-number":["BK20220617"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22201024"],"award-info":[{"award-number":["22201024"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010031","name":"Postdoctoral Research Foundation of China","doi-asserted-by":"publisher","award":["2023M730370"],"award-info":[{"award-number":["2023M730370"]}],"id":[{"id":"10.13039\/501100010031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018922","name":"Advanced Catalysis and Green Manufacturing Collaborative Innovation Center, Changzhou University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018922","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006711","name":"Changzhou University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bmcl.2025.130189","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T13:33:19Z","timestamp":1742218399000},"page":"130189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of hypoxic-activation prodrug TH-302 derivatives"],"prefix":"10.1016","volume":"122","author":[{"given":"Zhengyi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingchen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2025.130189_bb0005","first-page":"584","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130189_bb0010","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/cncr.35444","article-title":"Global cancer statistics 2022","volume":"130","author":"Nierengarten","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.bmcl.2025.130189_bb0015","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/jso.24592","article-title":"Global trends in esophageal cancer","volume":"115","author":"Malhotra","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.bmcl.2025.130189_bb0020","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.cell.2023.02.038","article-title":"SnapShot: Cancer chemotherapy","volume":"186","author":"Falzone","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2025.130189_bb0025","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Uttpal","year":"2023","journal-title":"Genes Dis"},{"key":"10.1016\/j.bmcl.2025.130189_bb0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pharmthera.2015.06.006","article-title":"Modulation of the tumor vasculature and oxygenation to improve therapy","volume":"153","author":"Siemann","year":"2015","journal-title":"Pharmaco Ther"},{"key":"10.1016\/j.bmcl.2025.130189_bb0035","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1628","article-title":"Disrupting tumour blood vessels","volume":"5","author":"Tozer","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmcl.2025.130189_bb0040","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00280-015-2920-7","article-title":"Targeting the hypoxic fraction of tumours using hypoxia activated prodrugs","volume":"77","author":"Phillips","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130189_bb0045","article-title":"Targeting hypoxia: hypoxia-activated prodrugs in cancer therapy","volume":"11","author":"Yue","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.bmcl.2025.130189_bb0050","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0223-5234(01)01253-3","article-title":"Prodrug strategies in cancer therapy","volume":"36","author":"Denny","year":"2001","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130189_bb0055","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.canlet.2014.11.020","article-title":"Hypoxia-activated prodrug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma","volume":"357","author":"Liapis","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmcl.2025.130189_bb0060","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1021\/cb4001537","article-title":"CH-01 is a hypoxia-activated prodrug that sensitizes cells to hypoxia\/reoxygenation through inhibition of Chk1 and Aurora a","volume":"8","author":"Cazares-K\u00f6rner","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmcl.2025.130189_bb0065","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1039\/B715270A","article-title":"Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds withanticancer potential","volume":"6","author":"Colucci","year":"2008","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.bmcl.2025.130189_bb0070","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1158\/1078-0432.CCR-16-0895","article-title":"Molecular pathways: hypoxia-activated prodrugs in cancer therapy","volume":"23","author":"Baran","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmcl.2025.130189_bb0075","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.1021\/acs.chemrev.6b00525","article-title":"Chemical design and synthesis of functionalized probes for imaging and treating tumor hypoxia","volume":"117","author":"Liu","year":"2017","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmcl.2025.130189_bb0080","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmcl.2025.130189_bb0085","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/1535-7163.MCT-11-0634","article-title":"Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302","volume":"11","author":"Meng","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmcl.2025.130189_bb0090","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood-2010-02-269126","article-title":"Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug","volume":"116","author":"Hu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2025.130189_bb0095","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1158\/1078-0432.CCR-14-3378","article-title":"Hypoxia-activated prodrug TH-302 targets hypoxic bone marrow niches in preclinical leukemia models","volume":"22","author":"Benito","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmcl.2025.130189_bb0100","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1158\/1078-0432.CCR-13-0674","article-title":"Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models","volume":"19","author":"Portwood","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmcl.2025.130189_bb0105","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/15384047.2016.1139268","article-title":"Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models","volume":"17","author":"Sun","year":"2016","journal-title":"Cancer Bio Ther"},{"key":"10.1016\/j.bmcl.2025.130189_bb0110","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1021\/jm0001020","article-title":"Synthesis and evaluation of nitroheterocyclic phosphoramidates as hypoxia-selective alkylating agents","volume":"43","author":"Borch","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130189_bb0115","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1021\/jm00113a040","article-title":"Nitroheterocycle reduction as a paradigm for intramolecular catalysis of drug delivery to hypoxic cells","volume":"34","author":"Firestone","year":"1991","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130189_bb0120","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nprot.2016.034","article-title":"Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs","volume":"11","author":"O\u2019connor","year":"2016","journal-title":"Nat Protoc"},{"key":"10.1016\/j.bmcl.2025.130189_bb0125","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1021\/acsmedchemlett.7b00355","article-title":"Synthesis and evaluation of radiolabeled phosphoramide mustard with selectivity for hypoxic cancer cells","volume":"8","author":"Zhang","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2025.130189_bb0130","series-title":"Phosphoramidate alkylator prodrugs. WO2007002931 (A2)","author":"Matteucci","year":"2007"},{"key":"10.1016\/j.bmcl.2025.130189_bb0135","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1039\/C5QO00211G","article-title":"Efficient synthesis of 2-nitroimidazole derivatives and the bioreductive clinical candidate evofosfamide (TH-302)","volume":"2","author":"JL","year":"2015","journal-title":"Org Chem Front"},{"key":"10.1016\/j.bmcl.2025.130189_bb0140","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1021\/jm701028q","article-title":"Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs","volume":"51","author":"Duan","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130189_bb0145","doi-asserted-by":"crossref","first-page":"95824","DOI":"10.18632\/oncotarget.21337","article-title":"Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept","volume":"8","author":"Voissiere","year":"2017","journal-title":"Oncotarget Ther"},{"key":"10.1016\/j.bmcl.2025.130189_bb0150","series-title":"Azolopyrimidine-based inhibitors of dipeptidyl peptidase iv and methods. US20050314470","author":"Wei","year":"2006"},{"key":"10.1016\/j.bmcl.2025.130189_bb0155","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1124\/jpet.111.180703","article-title":"Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy","volume":"337","author":"Gu","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmcl.2025.130189_bb0160","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1021\/jm00280a030","article-title":"Nitroheterocyclic antimicrobial agents. 1-methyl-2-nitro-5-imidazolyl derivatives","volume":"15","author":"Asato","year":"1972","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130189_bb0165","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/AAC.7.5.672","article-title":"Treatment of anaerobic infections with metronidazole","volume":"7","author":"Tally","year":"1975","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2025.130189_bb0170","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/03602530500364023","article-title":"Metabolism and transport of oxazaphosphorines and the clinical implications","volume":"37","author":"Zhang","year":"2005","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.bmcl.2025.130189_bb0175","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.2174\/0929867322666151021111016","article-title":"Hypoxia activated prodrugs factors influencing design and development","volume":"22","author":"Liang","year":"2015","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmcl.2025.130189_bb0180","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1021\/jm201717y","article-title":"Nitro seco analogues of the duocarmycins containing sulfonate leaving groups as hypoxia-activated prodrugs for cancer therapy","volume":"55","author":"Stevenosn","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130189_bb0185","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1021\/jm401546n","article-title":"Discovery of 1-methyl-1H-imidazole derivatives as potent jak2 inhibitors","volume":"57","author":"Su","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130189_bb0190","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1039\/D1AY01624E","article-title":"A simple colorimetric method for viable bacteria detection based on cell counting Kit-8","volume":"13","author":"Yang","year":"2021","journal-title":"Anal Methods"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25000988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25000988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:07:01Z","timestamp":1762344421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25000988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":38,"alternative-id":["S0960894X25000988"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130189","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of hypoxic-activation prodrug TH-302 derivatives","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130189","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130189"}}